D’Agate, Salvatore
Chavan, Chandrashekhar
Manyak, Michael
Palacios-Moreno, Juan Manuel
Oelke, Matthias
Michel, Martin C.
Roehrborn, Claus G.
Della Pasqua, Oscar http://orcid.org/0000-0002-6211-1430
Funding for this research was provided by:
GlaxoSmithKline
University College London
Article History
Received: 24 June 2020
Accepted: 30 October 2020
First Online: 18 December 2020
Compliance with ethical standards
:
: S. D’Agate has none to declare; M. Oelke has been a speaker, consultant and/or trial investigator for Apogepha, Astellas, Ferring, GSK, Pierre Fabre and Pfizer and received research grants from Astellas and Pfizer; M.C. Michel has been a speaker and consultant for Apogepha, Astellas, Dr. Willmar Schwabe, Ferring, GSK, Recordati and Velicept; he is a past employee of Boehringer Ingelheim and a current shareholder of Velicept; C.G. Roehrborn was previously employed as a consultant for GSK; C. Chavan, M. Manyak, J.M. Palacios-Moreno and O. Della Pasqua are GSK employees and hold stocks/shares in GSK.
: The current investigation describes the results from computer simulations and as such does not involve human participants and/or animals. Patient baseline characteristics used as basis for resampling were obtained from the pooled population enrolled in the clinical trials listed in the supplementary materials, all of which have been performed according to relevant ethical and clinical guidelines.
: All participants enrolled into the original clinical trials have given informed consent. The terms of consent include the scope of the research presented here.